



April 11, 2008

Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting

TUSTIN, Calif., April 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that the following preclinical abstracts will be the subject of oral and poster presentations at the 2008 Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego:

- "Targeting mutant p53 protein and tumor vasculature: An effective combination therapy for advanced breast tumors" (Abstract #2341, New Targets 1: Mechanisms Session) - Poster session scheduled for Monday, April 14, 2008 from 8:00 am to 12:00 pm.
- "An immunocytokine that binds to phosphatidylserine generates an effective cell-based tumor vaccine in mice" (Abstract #2841, Tumor Vaccines Session) - Poster session scheduled for Monday, April 14, 2008 from 1:00 pm to 5:00 pm.
- "Combination of a monoclonal anti-phosphatidylserine antibody with docetaxel strongly inhibits the growth and metastasis of hormone-refractory prostate cancers in mice" (Abstract #2551, New Approaches to Biological Therapy Session) - Oral presentation scheduled for Monday, April 14, 2008 at 2:10 pm.
- "Antibody targeting of phosphatidylserine produces a cytokine microenvironment that enhances innate anti-tumor immune responses" (Abstract #4079, Immunoconjugates, Peptides, and Protein Therapeutics Session) - Poster session scheduled for Tuesday, April 15, 2008 from 8:00 am to 12:00 pm.

Abstracts and information about the AACR and its Annual Meeting may be found at <http://www.aacr.org>.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (<http://www.avidbio.com>), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at <http://www.peregrineinc.com>.

Contacts:

GendeLindheim BioCom Partners
Investors
info@peregrineinc.com
(800) 987-8256

Media
Barbara Lindheim
(212) 918-4650

SOURCE Peregrine Pharmaceuticals, Inc.

<http://www.peregrineinc.com>

Copyright (C) 2008 PR Newswire. All rights reserved

News Provided by COMTEX